Psychiatric Symptoms in Parkinson's Disease

Overview

Journal Eur Arch Psychiatry Clin Neurosci

Specialties Neurology
Psychiatry

Date 2008 Dec 5

PMID 18985296

Citations 14

Authors

Frank Schneider

Astrid Althaus

Volker Backes

Richard Dodel

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder which is often reduced to a mere dysfunction of motor performance. Non-motor symptoms, however, are frequent impairments in PD and result in a major impact on the patients and their caregivers. The major neuropsychiatric comorbidities depression, anxiety, and psychotic symptoms are briefly discussed. Additionally, a brief outlook on deep brain stimulation and its effect on psychiatric symptoms is provided. Several studies did show that neuropsychiatric symptoms are underdiagnosed and consecutively treated inadequately. All in all more attention should be directed to the detection and treatment of psychiatric symptoms in PD patients in routine clinical settings.

Citing Articles

Perception of emotionally incongruent cues: evidence for overreliance on body vs. face expressions in Parkinson's disease.

Foul Y, Arkadir D, Demikhovskaya A, Noyman Y, Linetsky E, Snineh M Front Psychol. 2024; 15:1287952.

PMID: 38770252 PMC: 11103677. DOI: 10.3389/fpsyg.2024.1287952.

Behind the Mask: Parkinson's Disease and Depression.

Balasubramanian S, Mehmood K, Al-Baldawi S, Zuniga Salazar G, Zuniga D Cureus. 2024; 16(1):e52663.

PMID: 38380213 PMC: 10877222. DOI: 10.7759/cureus.52663.

Association of depression with disease duration, quality of life and adherence in Parkinson's disease: A cross sectional study.

Samanta S, Bisht M, Kanimozhi M, Kumar N, Handu S J Family Med Prim Care. 2023; 12(7):1406-1411.

PMID: 37649742 PMC: 10465023. DOI: 10.4103/jfmpc.jfmpc_2288_22.

Translational molecular imaging and drug development in Parkinson's disease.

Haider A, Elghazawy N, Dawoud A, Gebhard C, Wichmann T, Sippl W Mol Neurodegener. 2023; 18(1):11.

PMID: 36759912 PMC: 9912681. DOI: 10.1186/s13024-023-00600-z.

Neural cell adhesion molecule Negr1 deficiency in mouse results in structural brain endophenotypes and behavioral deviations related to psychiatric disorders.

Singh K, Jayaram M, Kaare M, Leidmaa E, Jagomae T, Heinla I Sci Rep. 2019; 9(1):5457.

PMID: 30932003 PMC: 6443666. DOI: 10.1038/s41598-019-41991-8.

References

Burn D . Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease. Mov Disord. 2002; 17(3):445-54. DOI: 10.1002/mds.10114. View

Castelli L, Perozzo P, Zibetti M, Crivelli B, Morabito U, Lanotte M . Chronic deep brain stimulation of the subthalamic nucleus for Parkinson's disease: effects on cognition, mood, anxiety and personality traits. Eur Neurol. 2006; 55(3):136-44. DOI: 10.1159/000093213. View

Veazey C, Aki S, Cook K, Lai E, Kunik M . Prevalence and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2005; 17(3):310-23. DOI: 10.1176/jnp.17.3.310. View

Vazquez A, Jimenez-Jimenez F, Garcia-Ruiz P . "Panic attacks" in Parkinson's disease. A long-term complication of levodopa therapy. Acta Neurol Scand. 1993; 87(1):14-8. View

Stein M, Heuser I, Juncos J, Uhde T . Anxiety disorders in patients with Parkinson's disease. Am J Psychiatry. 1990; 147(2):217-20. DOI: 10.1176/ajp.147.2.217. View

Rojo A, Aguilar M, Garolera M, Cubo E, Navas I, Quintana S . Depression in Parkinson's disease: clinical correlates and outcome. Parkinsonism Relat Disord. 2003; 10(1):23-8. DOI: 10.1016/s1353-8020(03)00067-1. View

Oertel W, Hoglinger G, Caraceni T, Girotti F, Eichhorn T, Spottke A . Depression in Parkinson's disease. An update. Adv Neurol. 2001; 86:373-83. View

Brown R, Jahanshahi M . Depression in Parkinson's disease: a psychosocial viewpoint. Adv Neurol. 1995; 65:61-84. View

Schuurman A, van den Akker M, Ensinck K, Metsemakers J, Knottnerus J, Leentjens A . Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology. 2002; 58(10):1501-4. DOI: 10.1212/wnl.58.10.1501. View

10.

Schneider F, Habel U, Volkmann J, Regel S, Kornischka J, Sturm V . Deep brain stimulation of the subthalamic nucleus enhances emotional processing in Parkinson disease. Arch Gen Psychiatry. 2003; 60(3):296-302. DOI: 10.1001/archpsyc.60.3.296. View

11.

Fernandez H, Aarsland D, Fenelon G, Friedman J, Marsh L, Troster A . Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord. 2008; 23(4):484-500. DOI: 10.1002/mds.21875. View

12.

Reijnders J, Ehrt U, Weber W, Aarsland D, Leentjens A . A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord. 2007; 23(2):183-9. DOI: 10.1002/mds.21803. View

13.

Aarsland D, Larsen J, Cummins J, Laake K . Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol. 1999; 56(5):595-601. DOI: 10.1001/archneur.56.5.595. View

14.

Weintraub D, Morales K, Moberg P, Bilker W, Balderston C, Duda J . Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord. 2005; 20(9):1161-9. PMC: 1989731. DOI: 10.1002/mds.20555. View

15.

Riedel O, Klotsche J, Spottke A, Deuschl G, Forstl H, Henn F . Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol. 2008; 255(2):255-64. DOI: 10.1007/s00415-008-0720-2. View

16.

Fenelon G, Mahieux F, Huon R, Ziegler M . Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain. 2000; 123 ( Pt 4):733-45. DOI: 10.1093/brain/123.4.733. View

17.

Kerenyi L, Ricaurte G, Schretlen D, McCann U, Varga J, Mathews W . Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch Neurol. 2003; 60(9):1223-9. DOI: 10.1001/archneur.60.9.1223. View

18.

Weisskopf M, Chen H, Schwarzschild M, Kawachi I, Ascherio A . Prospective study of phobic anxiety and risk of Parkinson's disease. Mov Disord. 2003; 18(6):646-51. DOI: 10.1002/mds.10425. View

19.

von Campenhausen S, Bornschein B, Wick R, Botzel K, Sampaio C, Poewe W . Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol. 2005; 15(4):473-90. DOI: 10.1016/j.euroneuro.2005.04.007. View

20.

Fernandez H, Trieschmann M, Burke M, Jacques C, Friedman J . Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord. 2003; 18(5):510-4. DOI: 10.1002/mds.10374. View